Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8298141 | 0.86 | ALDH1A1 (0.60) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL20729406 | 0.84 | TAS1R3 (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL18948447 | 0.84 | SMN1; SMN2 (0.40) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL18885070 | 0.84 | TSHR (0.57) | ACHENPSR1 | |
| SCHEMBL10843568 | 0.84 | ACHE (0.51) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL22932925 | 0.83 | PPARG (0.50) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL26874497 | 0.82 | CA1 (0.52) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL27457959 | 0.82 | ACHE (0.38) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL7179479 | 0.81 | PPARG (0.49) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL13045900 | 0.81 | PPARG (0.49) | ALDH1A1LMNATP53MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-01-14 | — | — | US | disclosed |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-10544143-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-10351555-B2 | Inhibitors of β-hydroxylase for treatment of cancer | MIDWESTERN UNIVERSITY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| US-7652017-B2 | Remedies and/or preventives for nervous system disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | SATOU NAOYA | 2008-05-15 | — | — | US | disclosed |
| WO-2003009897-A1 | MEDICAMENT INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | MITSUBISHI PHARMA CORPORATION (JP) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | QPCT, QPCTL, GLUL | ALDH1A1 3779/4885LMNA 4302/4885TP53 1883/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 665/4885LMNA 3424/4885TP53 4094/4885 |
| US-10544143-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | ALDH1A1 1039/4885LMNA 3331/4885TP53 2293/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | ALDH1A1 529/4885LMNA 3816/4885TP53 2974/4885 |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | GPR119, P2RY14, P2RY4 | ALDH1A1 1845/4885LMNA 3487/4885TP53 2673/4885 |
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | ATP2A1, ATP2A2, ATP2A3 | ALDH1A1 2313/4885LMNA 947/4885TP53 381/4885 |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | AAAS, PROC, AADAC | ALDH1A1 2104/4885LMNA 189/4885TP53 1699/4885 |
| US-10351555-B2 | Inhibitors of β-hydroxylase for treatment of cancer | ASPH, CYP46A1, AHR | ALDH1A1 42/4885LMNA 2362/4885TP53 828/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ALDH1A1 2295/4885LMNA 4450/4885TP53 3234/4885 |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | ALDH1A1 1039/4885LMNA 3331/4885TP53 2293/4885 |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR7, TLR1, TLR9 | ALDH1A1 3139/4885LMNA 4181/4885TP53 2120/4885 |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | AAAS, PROC, AADAC | ALDH1A1 2104/4885LMNA 189/4885TP53 1699/4885 |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR1, TLR7, TLR9 | ALDH1A1 1511/4885LMNA 3147/4885TP53 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.